Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

779.67 -2.71 (-0.35%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

49 50 Next >

Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review ↗

May 03, 2024

The Nasdaq regained its 50-day line Friday. The other indexes hit resistance.

Via Investor's Business Daily

Topics Economy

Assessing Regeneron Pharmaceuticals: Insights From 16 Financial Analysts ↗

May 03, 2024

Via Benzinga

Shhh! 3 Secret Pharma Stocks Flying Below Wall Street’s Radar ↗

May 03, 2024

Discover three under-the-radar pharma stocks poised for significant growth in 2024. Explore their product pipelines and potential gains.

Via InvestorPlace

Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation ↗

May 02, 2024

Regeneron Pharmaceuticals Q1 2024 earnings: EPS down 5%, sales miss; Eylea US sales drop 16%, Dupixent offsets. Oncology treatment Libtayo sales surge 49%.

Via Benzinga

Industry Comparison: Evaluating Regeneron Pharmaceuticals Against Competitors In Biotechnology Industry ↗

May 02, 2024

Via Benzinga

Regeneron Earnings Miss; Biotech Giant's Stock Falls ↗

May 02, 2024

The biotech giant's earnings and sales both missed Q1 estimates.

Via Investor's Business Daily

Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends ↗

April 30, 2024

Via Benzinga

Wall Street Inches Up After Powell's Inflation Remarks; Chipmakers Rebound; Gold, Crude Falter: What's Driving Markets Thursday? ↗

May 02, 2024

U.S. stock markets surged during Thursday’s midday trading session in New York, with major averages all showing gains.

Via Benzinga

Topics Economy

REGN Stock Earnings: Regeneron Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 ↗

May 02, 2024

REGN stock results show that Regeneron Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years ↗

May 02, 2024

Via Benzinga

Market Analysis: Regeneron Pharmaceuticals And Competitors In Biotechnology Industry ↗

April 18, 2024

Via Benzinga

If You Invested $100 In This Stock 20 Years Ago, You Would Have $6,700 Today ↗

April 17, 2024

Via Benzinga

Breaking Down Regeneron Pharmaceuticals: 13 Analysts Share Their Views ↗

April 12, 2024

Via Benzinga

3 Biotech Stocks to Buy and Hold Through 2030 and Beyond ↗

May 02, 2024

It pays to develop novel medicines for life-threatening illnesses.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

April 30, 2024

Via Benzinga

AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study ↗

April 25, 2024

AbbVie's Upadacitinib outperforms dupilumab in Phase 3b/4 study for atopic dermatitis treatment, achieving superior efficacy and rapid skin clearance than Dupixent.

Via Benzinga

2 Small-Cap Growth Stocks With Room To Run ↗

April 24, 2024

These two small-cap growth stocks could be ready to run.

Via The Motley Fool

Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick ↗

April 17, 2024

Amgen's Tezspire shows promising COPD trial results and potential market expansion beyond asthma. Comparison with Dupixent reveals significant benefits for eosinophil counts ≥150 cells/μL and ≥300...

Via Benzinga

Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking ↗

April 11, 2024

Via Benzinga

Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends ↗

March 28, 2024

Via Benzinga

Decoding 12 Analyst Evaluations For Regeneron Pharmaceuticals ↗

March 26, 2024

Via Benzinga

Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review ↗

April 12, 2024

The stock market gave some bullish signs, with Nvidia rebounding, but the indexes generally fell for the week on inflation and Mideast fears.

Via Investor's Business Daily

Topics Economy

Eye Drug Eylea Price Manipulation: Regeneron Faces US Justice Department Allegations Over Medicare Pricing Of Its Best-Selling Eye Drug ↗

April 11, 2024

The U.S. Justice Department accuses Regeneron Pharmaceuticals of Medicare fraud related to its macular degeneration drug, Eylea. Allegations include manipulating drug prices, resulting in inflated...

Via Benzinga

Topics Fraud

Are Regeneron's Legal Troubles — And Six-Week Slide — A Buying Opportunity? ↗

April 11, 2024

Regeneron has fallen more than 6% over the past six weeks, and dropped again Thursday, as the DOJ focuses on its Eylea franchise.

Via Investor's Business Daily

Should You Sell This Stock Following a Regulatory Roadblock? ↗

April 05, 2024

It's not the first such obstacle this high-performing drugmaker has faced.

Via The Motley Fool

5 Healthcare Stocks to Buy for 2024 ↗

April 02, 2024

Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up.

Via InvestorPlace

Topics Artificial Intelligence

Here's How Much $100 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth Today ↗

April 01, 2024

Via Benzinga

Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback ↗

March 28, 2024

The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.

Via Investor's Business Daily

Stock-Split Watch: Are These 2 Top Growth Stocks Next? ↗

March 28, 2024

Shares of Eli Lilly and Regeneron are both well into the range where splits would make sense.

Via The Motley Fool

3 Biotech Stocks to Buy for the Next Bull Run: March 2024 ↗

March 26, 2024

These biotech stocks to buy are well positioned for growth, and will generate solid returns for investors in the next bull run.

Via InvestorPlace

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

49 50 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Regeneron Pharmaceuticals (NQ:REGN)

Headline News about Regeneron Pharmaceuticals

Starting at $3.75/week.

Subscribe Today